The Collection and Storage of Umbilical Cord Blood for Transplantation
Launched by M.D. ANDERSON CANCER CENTER · Nov 13, 2012
Trial Information
Current as of May 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on collecting and storing blood from the umbilical cords of newborn babies right after they are born. This cord blood contains valuable stem cells that can be used for bone marrow transplants for patients in need. By participating in this study, the collected cord blood may be stored in the MD Anderson Cord Blood Bank and could be made available to patients who do not have a suitable donor. The program is part of a larger effort, supported by the government, to ensure that these life-saving resources are accessible to those who need them.
To be eligible for this trial, pregnant women must be at least 18 years old and able to give their consent for the collection of cord blood. Participants will need to provide some medical history and agree to testing for certain infections and blood types. After collection, if the cord blood does not meet the required standards for patient use, it may still be used for research or quality improvement purposes, or it may be discarded. Overall, this trial aims to help improve treatment options for patients requiring transplants while also contributing to medical research.
Gender
FEMALE
Eligibility criteria
- • Inclusion Criteria
- • 1. Pregnant women age 18 or older. Cord blood will not be collected from a minor.
- • 2. Able to give verbal informed consent prior to collection of the cord blood.
- • 3. Able to give written informed consent prior to collection of the cord blood.
- • 4. Willing to provide a personal and family medical history (if available) of herself and the biologic father (if available), prior to or following collection of the cord blood.
- • 5. Willing to consent to testing of her blood and the cord blood for infectious diseases, including human immunodeficiency virus (HIV), human T cell lymphotrophic virus (HTLV), hepatitis B and C, cytomegalovirus (CMV), syphilis (RPR), Trypanosoma cruzi (Chagas) and West Nile Virus (WNV). Incomplete tests or positive infectious disease testing results may result in the cord blood unit being deemed unacceptable for clinical use.
- • 6. Willing to consent to testing the cord blood for HLA type, ABO/RhD type, newborn screening and microbial cultures.
- Exclusion Criteria:
- • N/A
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Elizabeth Shpall, MD
Study Chair
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials